A New Window into Inspection Findings

The U.S. Food and Drug Administration (FDA) has expanded public access to regulatory information through its FOIA Electronic Reading Room, making large datasets from inspections and compliance activities available for public review and analysis. For professionals working in regulated industries, especially medical devices, these datasets provide a rare opportunity to examine regulatory enforcement patterns across thousands of inspections.

The Freedom of Information Act (FOIA) requires federal agencies to make certain records available to the public. In addition to responding to individual requests, agencies often publish frequently requested materials in an “electronic reading room.” FDA’s updated reading room now includes structured datasets that summarize inspection findings across multiple program areas, including foods, drugs, biologics, veterinary medicine, and medical devices.

One particularly valuable dataset contains detailed records of inspection findings issued during FDA inspections from 2008 through early 2026. The dataset includes more than 270,000 inspection observations linked to over 70,000 inspections conducted across tens of thousands of facilities. Each record includes information such as the inspected firm, inspection date, regulatory citation, and a short and long description of the observation.

Significance to Regulatory and Quality Professionals

For regulatory and quality professionals, the significance of this dataset lies not only in its size but also in the transparency it provides into how FDA inspectors document compliance concerns. The data includes citations to specific sections of the Code of Federal Regulations (CFR), allowing analysts to identify which regulatory requirements are most frequently cited during inspections.

While the dataset spans multiple regulatory program areas, medical device inspections represent a substantial portion of the observations. Device-related findings frequently reference sections of the Quality System Regulation (21 CFR Part 820), including requirements related to corrective and preventive action (CAPA), complaint handling, internal audits, process validation, and design controls. These categories have historically been central to FDA enforcement actions and continue to represent common areas of regulatory concern.

Practical Benefits

The availability of this data provides several practical benefits for industry professionals:

Inspection trend analysis. Organizations can study which regulatory requirements are most frequently cited during inspections and evaluate whether their own quality systems address these areas effectively.

Training and education. Real-world inspection findings provide valuable case examples for training quality and regulatory teams.

Risk-based quality management. By understanding the patterns of inspection observations, organizations can prioritize internal audits and compliance efforts around areas that historically present the greatest regulatory risk.

Regulatory research. The dataset allows analysts to explore how inspection practices and enforcement trends have evolved over time.

For those involved in quality management systems and regulatory compliance, datasets like this highlight an important reality. While regulatory frameworks evolve, such as the transition from the Quality System Regulation (QSR) to the Quality Management System Regulation (QMSR), many of the operational challenges identified during inspections remain consistent. Issues related to documentation, procedure implementation, complaint handling, and corrective action systems continue to be recurring themes in inspection observations.

Coming Next

In the coming months, we will post information in the MDP FOIA Reading Room as we explore datasets in greater depth, focusing particularly on medical device inspection findings. By analyzing the most frequently cited requirements and examining how they map to current quality system expectations, we can better understand the practical compliance challenges organizations face and identify opportunities for improving quality system effectiveness.

The FDA’s FOIA Electronic Reading Room represents an important step toward greater transparency in regulatory oversight. For regulatory professionals, quality leaders, and educators, it also provides a powerful resource for learning from the collective experience of thousands of inspections across the regulated industry.